These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 22414602)

  • 41. Molecular breakdown: a comprehensive view of anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
    Noh KW; Lee MS; Lee SE; Song JY; Shin HT; Kim YJ; Oh DY; Jung K; Sung M; Kim M; An S; Han J; Shim YM; Zo JI; Kim J; Park WY; Lee SH; Choi YL
    J Pathol; 2017 Nov; 243(3):307-319. PubMed ID: 28741662
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The novel hsa-miR-12528 regulates tumourigenesis and metastasis through hypo-phosphorylation of AKT cascade by targeting IGF-1R in human lung cancer.
    Jeon SH; Yoo JK; Kim CM; Lim ES; Lee SJ; Lee JM; Oh SH; Kim JK
    Cell Death Dis; 2018 May; 9(5):493. PubMed ID: 29712908
    [TBL] [Abstract][Full Text] [Related]  

  • 43. MicroRNA expression profiles and clinicopathological implications in lung adenocarcinoma according to EGFR, KRAS, and ALK status.
    Kim H; Yang JM; Jin Y; Jheon S; Kim K; Lee CT; Chung JH; Paik JH
    Oncotarget; 2017 Jan; 8(5):8484-8498. PubMed ID: 28035073
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Involvement of Grb2 adaptor protein in nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-mediated signaling and anaplastic large cell lymphoma growth.
    Riera L; Lasorsa E; Ambrogio C; Surrenti N; Voena C; Chiarle R
    J Biol Chem; 2010 Aug; 285(34):26441-50. PubMed ID: 20554525
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Down-regulation of c-Met and Bcl2 by microRNA-206, activates apoptosis, and inhibits tumor cell proliferation, migration and colony formation.
    Sun C; Liu Z; Li S; Yang C; Xue R; Xi Y; Wang L; Wang S; He Q; Huang J; Xie S; Jiang W; Li D
    Oncotarget; 2015 Sep; 6(28):25533-74. PubMed ID: 26325180
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.
    Boland JM; Erdogan S; Vasmatzis G; Yang P; Tillmans LS; Johnson MR; Wang X; Peterson LM; Halling KC; Oliveira AM; Aubry MC; Yi ES
    Hum Pathol; 2009 Aug; 40(8):1152-8. PubMed ID: 19386350
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The expression and oncogenic effects of the embryonic stem cell marker SALL4 in ALK-positive anaplastic large cell lymphoma.
    Wang P; Zhang JD; Wu F; Ye X; Sharon D; Hitt M; McMullen TP; Hegazy SA; Gelebart P; Yang J; Ma Y; Lai R
    Cell Signal; 2012 Oct; 24(10):1955-63. PubMed ID: 22743134
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Partial deletion of the ALK gene in ALK-positive anaplastic large cell lymphoma.
    Fukuhara S; Nomoto J; Kim SW; Taniguchi H; Miyagi Maeshima A; Tobinai K; Kobayashi Y
    Hematol Oncol; 2018 Feb; 36(1):150-158. PubMed ID: 28665006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The emerging pathogenic and therapeutic importance of the anaplastic lymphoma kinase gene.
    Kelleher FC; McDermott R
    Eur J Cancer; 2010 Sep; 46(13):2357-68. PubMed ID: 20451371
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A new target in non-small cell lung cancer: EML4-ALK fusion gene].
    Wang H; Yuan J; Ma Z
    Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):538-42. PubMed ID: 21645460
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ablation of oncogenic ALK is a viable therapeutic approach for anaplastic large-cell lymphomas.
    Piva R; Chiarle R; Manazza AD; Taulli R; Simmons W; Ambrogio C; D'Escamard V; Pellegrino E; Ponzetto C; Palestro G; Inghirami G
    Blood; 2006 Jan; 107(2):689-97. PubMed ID: 16189272
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Molecular characterization of the t(2;5) (p23; q35) translocation in anaplastic large cell lymphoma (Ki-1) and Hodgkin's disease.
    Yee HT; Ponzoni M; Merson A; Goldstein M; Scarpa A; Chilosi M; Menestrina F; Pittaluga S; de Wolf-Peeters C; Shiota M; Mori S; Frizzera G; Inghirami G
    Blood; 1996 Feb; 87(3):1081-8. PubMed ID: 8562933
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The transcription factors Ik-1 and MZF1 downregulate IGF-IR expression in NPM-ALK⁺ T-cell lymphoma.
    Vishwamitra D; Curry CV; Alkan S; Song YH; Gallick GE; Kaseb AO; Shi P; Amin HM
    Mol Cancer; 2015 Feb; 14():53. PubMed ID: 25884514
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sonic hedgehog signaling pathway is activated in ALK-positive anaplastic large cell lymphoma.
    Singh RR; Cho-Vega JH; Davuluri Y; Ma S; Kasbidi F; Milito C; Lennon PA; Drakos E; Medeiros LJ; Luthra R; Vega F
    Cancer Res; 2009 Mar; 69(6):2550-8. PubMed ID: 19244133
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small-cell lung cancer cells.
    Wang R; Deng X; Yoshioka Y; Vougiouklakis T; Park JH; Suzuki T; Dohmae N; Ueda K; Hamamoto R; Nakamura Y
    Cancer Sci; 2017 Jun; 108(6):1203-1209. PubMed ID: 28370702
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.
    Katayama R
    Cancer Sci; 2018 Mar; 109(3):572-580. PubMed ID: 29336091
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.
    Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G
    Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antitumor activity of pyridoisoquinoline derivatives F91873 and F91874, novel multikinase inhibitors with activity against the anaplastic lymphoma kinase.
    Kruczynski A; Mayer P; Marchand A; Vispé S; Fournier E; Annereau JP; Brel V; Barret JM; Delsol G; Imbert T; Fahy J; Bailly C
    Anticancer Drugs; 2009 Jun; 20(5):364-72. PubMed ID: 19322071
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors.
    McDermott U; Iafrate AJ; Gray NS; Shioda T; Classon M; Maheswaran S; Zhou W; Choi HG; Smith SL; Dowell L; Ulkus LE; Kuhlmann G; Greninger P; Christensen JG; Haber DA; Settleman J
    Cancer Res; 2008 May; 68(9):3389-95. PubMed ID: 18451166
    [TBL] [Abstract][Full Text] [Related]  

  • 60. ALK gene aberrations and the JUN/JUNB/PDGFR axis in metastatic NSCLC.
    Berghoff AS; Birner P; Streubel B; Kenner L; Preusser M
    APMIS; 2014 Sep; 122(9):867-72. PubMed ID: 24750504
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.